SNSE - Sensei Bio Short-Term Debt to Capital

Symbol and logo of brand Sensei Biotherapeutics, Inc. (SNSE)

Sensei Biotherapeutics (SNSE) develops antibodies to combat tumors, planning to expand its oncology presence through B2B deals. Meanwhile, the company delegates all clinical trials to external contractors, achieving high operational efficiency. This price chart, which assists in the basic asset valuation, demonstrates the 0.08 indicator. Business development relies on close collaboration with leading scientific centers and clinics to implement innovations.

Current Liabilities to Capital: senseibio.com (SNSE) for 07/04/2022 - 06/16/2026

Summary analytical data breakdowns for Sensei Bio (SNSE)

- stock value and consensus price forecast:
Price Chart Sensei Biotherapeutics|SNSE - Broker Consensus Forecast
- market capitalization statistics:
Market Capitalization Sensei Biotherapeutics Inc|SNSE - Real Price to Acquire Entire Company
- book capitalization information:
Net Assets per Single Share Sensei Biotherapeutics|SNSE - Total Stockholders' Equity|Market Value to Book Value Ratio senseibio.com|SNSE - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Debt to Equity Sensei Biotherapeutics|SNSE - Long-Term Liabilities to Capital|Short-Term Debt to Capital Sensei Biotherapeutics|SNSE - Company Total Indebtedness|Debt to Book Value Sensei Biotherapeutics Inc|SNSE - Long-Term Debt|Company Current Liabilities Sensei Biotherapeutics|Quick Ratio senseibio.com
- company profitability and valuation multiples indicators:
SNSE - Net Financial Result
Initial company analysis:Sensei Biotherapeutics, Inc. SNSE
Signature product of Sensei Bio

This ratio measures the proportion of liabilities maturing within one year relative to equity, reflecting the intensity of short-term debt financing used to maintain liquidity. For Sensei Biotherapeutics (SNSE), whose expenses are limited to laboratory standards and reagent safety, the history of short-term loans to equity serves as an indicator of operational flexibility in financing clinical trials.

Competitors of Sensei Biotherapeutics (SNSE)

Short-Term Debt to Equity ImmunityBio Corp (IBRX)|Immunocore Corp - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital JANX (Janux Therapeutics)|RCUS - Short-Term Debt to Equity Ratio|ZYME - Short-Term Debt to Equity|Current Liabilities to Capital Tango Therapeutics Inc|Iovance (IOVA) - Short-Term Debt to Equity|IMTX (Immatics Biotechnologies) - Short-Term Debt to Equity|Short-Term Debt to Equity Xencor, Inc.|Current Liabilities to Capital compasstherapeutics.com CMPX|Short-Term Debt to Capital REPL|Lyell (LYEL) - Short-Term Indebtedness to Equity|Innate Pharma, S.A. - Short-Term Debt to Equity Ratio|Pyxis Oncology Inc. (PYXS) - Current Liabilities to Capital|CGEN: Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital IOBT (iobiotech.com)|STRO: Short-Term Debt to Capital|INKT - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Werewolf Therapeutics Inc.|Short-Term Debt to Equity Ratio Immix (IMMX)|Short-Term Debt to Equity ALX Oncology (ALXO)|Short-Term Debt to Equity Ratio Cue Biopharma Inc. CUE|PDS Biotechnology Corporation - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital Sonnet BioTherapeutics Holdings, Inc. SONN|MAIA - Short-Term Debt to Equity|LIMN (Liminatus) - Short-Term Debt to Capital Ratio|lavatherapeutics.com (LVTX) - Short-Term Debt to Equity|Current Liabilities to Capital nextcure.com (NXTC)|Short-Term Debt to Equity Ratio LPTX|INTS - Short-Term Indebtedness to Equity|Short-Term Debt to Equity Ratio TOVX (Synthetic Biologics)|Short-Term Loans to Capital Ratio GRTS|Short-Term Debt to Capital KA (Kineta, Inc.)|Ratio of Short-Term Indebtedness to Capital NEXI|Turnstone Biologics Corporation - Short-Term Debt to Capital|Current Liabilities to Capital Vaccinex Inc.|Harpoon Tx (HARP) - Short-Term Debt to Equity